Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7

Journal of Immunology

Volumn 161, Issue 4, 1998, Pages 1901-1907

  Nakajima, Atsuo ^a,b,c   Kodama, Tomohiro ^b   Morimoto, Shinji ^b   Azuma, Miyuki ^d,e   Takeda, Kazuyoshi ^b   Oshima, Hideo ^b,f   Yoshino, Shin Ichi ^c   Yagita, Hideo ^b,e   Okumura, Ko ^b,e  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; FEMALE; GENE THERAPY; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD80; ANTINEOPLASTIC AGENTS; CD40 LIGAND; FEMALE; GRAFT REJECTION; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MAST-CELL SARCOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSFECTION; UP-REGULATION;

EID: 0032529217     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
2. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
3. Pel, V. A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J.-C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by CTL. Immunol. Rev. 145:229.
4. Parmiani, G. 1993. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today 14:536.
5. Elliot, B. E., D. A. Carlow, A.-M. Rodricks, and A. Wade. 1989. Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53:181.
6. Seliger, B., M. J. Maeurer, and S. Ferrone. 1997. TAP off-tumors on. Immunol. Today 18:292.
7. Roszman, T., L. Elliott, and W. Brooks. 1991. Modulation of T-cell function by glioma. Immunol. Today 12:370.
8. Mueller, D. L., M. K. Jenkins, and R. H. Schwartz. 1989. Clonal expansion vs functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:445.
9. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
10. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
11. Sperling, A. I., and J. A. Bluestone. 1996. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153:155.
12. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
13. + T cells by B7-transfected melanoma cells. Science 259:368.
14. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen. 1995. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154:2794.
15. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
16. Ding, L., and E. M. Shevach. 1996. Activated B cells express CD28/B7-independent costimulatory activity. J. Immunol. 157:1389.
17. Shinde, S., Y. Wu, Y. Guo, Q. Niu, J. Xu, I. S. Grewal, R. Flavell, and Y. Liu. 1996. CD40L is important for induction of, but not response to, costimulatory activity: ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J. Immunol. 157:2764.
18. Guo, Y., S. Shinde, M.-S. Sy, A. Aruffo, and Y. Lie. 1996. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J. Exp. Med. 184:955.
19. Durie, F. H., T. M. Foy, S. R. Masters, J. D. Lamen, and R. J. Noelle. 1994. The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol. Today 15:406.
20. + T-cell response. Immunol. Today 17:410.
21. Grewal, I., and R. A. Flavell. 1996. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153:87.
22. Kamanaka, M., P. Yu, T. Yasui, K. Yoshida, T. Kawabe, T. Horii, T. Kishimoto, and H. Kikutani. 1996. Protective role of CD40 in Leishmania major infected at two distinct phases of cell-mediated immunity. Immunity 4:275.
23. Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, and C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4:283.
24. Soong, L., J.-C. Xu, I. S. Grewall, P. Kima, J. Sun, J. Longley, Jr., N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an susceptibility to Leishmania amazonensis infection. Immunity 4:263.
25. Durie, F. H., A. Aruffo, J. Ledbetter, K. M. Crassi, W. R. Green, L. D. Fast, and R. J. Noelle. 1994. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J. Clin. Invest. 94:1333.
26. Gerritse K., J. D. Laman, R. J. Noelle, A. Aruffo, J. A. Ledbetter, W. J. A. Boersma, and E. Claasen. 1996. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 93:2499.
27. Larsen, C. P., D. Z. Alexander, D. Hollenbaugh, E. T. Elwood, S. C. Ritchie, A. Aruffo, R. Hendrix, and T. C. Pearson. 1996. CD40-gp39 interaction play a critical role during allograft rejection. Transplantation 61:4.
28. Noelle, R. J. 1996. CD40 and its ligand in host defense. Immunity 4:415.
29. Alderson, M. R., R. J. Armitage, T. W. Tough, L. Stockbine, W. C. Fanslow, and M. K. Spriggs. 1993. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J. Exp. Med. 178: 669.
30. Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzio, J. Hakimi, M. Gately, and G. Delespesse. 1995. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125.
31. Kato, T., R. Hakamada, H. Yamane, and H. Nariuchi. 1996. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophage via CD40-CD40 ligand interaction. J. Immunol. 156:3932.
32. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
33. + hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J. Exp. Med. 185:341.
34. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
35. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: up-regulation via MHC and CD40 molecules and down-regulation by IL-4 and IL-10. J. Exp. Med. 184:741.
36. de Boer, M., A. Kasran, J. Kwekkeboom, H. Walter, P. Vandenberghe, and J. L. Ceuppens. 1993. Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur. J. Immunol. 23:3120.
37. Yang, Y., and J. M. Wilson. 1996. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science 273:1862.
38. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr., and R. A. Flavell. 1996. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273:1864.
39. Mackey, M. F., J. R. Gunn, P. P. Ting, H. Kikutani, G. Dranoff, R. J. Noelle, and R. J. Barth Jr. 1997. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 57:2569.
40. Dilloo, D., M. Brown, M. Roskrow, W. Zhong, M. Holladay, W. Holden, and M. Brenner. 1997. CD40 ligand induces an antileukemia response in vivo. Blood 90:1927.
41. Grossmann, M. E., M. P. Brown, and M. K. Brenner. 1997. Antitumor responses induced by transgenic expression of CD40 ligand. Hum. Gene Ther. 8:1935.
42. Armitage, R. J., W. C. Fanslow, L. Strockbine, T. A. Sato, K. N. Clifford, B. M. MaCduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, E. D. Clark, C. A. Smith, K. H. Grabstein, D. Cosman, and M. K. Spriggs. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80.
43. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule. Eur. J. Immunol. 25:3060.
44. Nuriya, S., H. Yagita, K. Okumura, and M. Azuma. 1996. The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Int. Immunol. 8:917.
45. Ossendorp, F., E. Mengede, M. Camps, R. Filius, and C. J. M. Mekief. 1998. Specific T helper cell requirement for optimal induction of CTL against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
46. Armitage, R. J., T. W. Tough, B. M. Macduff, W. C. Fanslow, M. K. Spriggs, F. Ramsdell, and M. R. Alderson. 1993. CD40 ligand is a T cell growth factor. Eur. J. Immunol. 23:2326.
47. Yang, G., M. T. Mizumo, K. E. Hellstrom, and L. Chen. 1997. B7-negative vs B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol. 158:851.
48. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156: 2909.
49. Peng, X., A. Kasran, P. A. M. Warmerdam, M. de Boer, and J. L. Ceuppens. 1996. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for IFN-γ production. Eur. J. Immunol. 26:1621.
50. van Essen, D., H. Kikutani, and D. Gray. 1995. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 378:620.
51. Hancock, W. W., M. H. Sayegh, X.-G. Zheng, R. Peach, P. S. Linsley, and L. A. Turka. 1996. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. USA 93:13967.
52. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Winn, and T. C. Pearson. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
53. Havell, E. A., W. Fier, and R. J. North. 1988. The antitumor function of tumor necrosis factor (TNF). J. Exp. Med. 167:1067.
54. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF: a primary mediator of the host response. Annu. Rev. Immunol. 7:625.
55. Wiley, J. A., R. Geha, and A. G. Harmsen. 1997. Exogenous CD40 ligand induces a pulmonary inflammation response. J. Immunol. 158:2932.